Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. - Wikidata - wikimedia - TriplyDB

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.

http://www.wikidata.org/entity/Q33267693

about

Imaging coagulation reactions in vivo Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo.RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents.Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins Dynamin-related protein-1 controls fusion pore dynamics during platelet granule exocytosis.Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network.Deposition of fibrinogen on the surface of in vitro thrombi prevents platelet adhesion Membrane Ballooning in Aggregated Platelets is Synchronised and Mediates a Surge in Microvesiculation.New insights into the spatiotemporal localization of prothrombinase in vivo.Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study A critical role for extracellular protein disulfide isomerase during thrombus formation in mice.Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Differential signaling by protease-activated receptors: implications for therapeutic targeting.Laser-induced endothelial cell activation supports fibrin formation.Thiol isomerases in thrombus formation.Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1.Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.Platelets and their chemokines in atherosclerosis-clinical applications.A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity.Agonist-induced platelet procoagulant activity requires shear and a Rac1-dependent signaling mechanism.Shaping the platelet response to vascular injury.Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models.Defective PDI release from platelets and endothelial cells impairs thrombus formation in Hermansky-Pudlak syndrome Relipidated tissue factor linked to collagen surfaces potentiates platelet adhesion and fibrin formation in a microfluidic model of vessel injury.A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice Protease-activated receptors in cancer: A systematic review.Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets.Necrotic platelets provide a procoagulant surface during thrombosis Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1.The transition of prothrombin to thrombin.A membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood Antiplatelet agents in clinical practice and their haemorrhagic risk.Platelet receptors and signaling in the dynamics of thrombus formation.

P2860

Q26995239-39B97D90-BC59-48AB-8563-C4F000A680CF Q28509120-0681CEF7-3E5E-41B4-BDCB-5F81D5132386 Q28509969-6F662840-8E3C-46C0-BFDF-1332909ADE6D Q30497540-6BD2EED3-7B9C-45C3-A5C0-FCC767D16485 Q30498047-6F195948-4EB1-4209-9AD8-0B69E14D9DE2 Q30501624-DBACC439-421A-4000-9481-CE32588BC9CA Q30514535-BAB40946-D8EC-4EE4-9583-939FFB0148CB Q30521428-C6D754E4-64F2-49B1-BA5C-B5ED572D0C86 Q30535815-098C9232-D793-40B2-8B2C-0FAC4F7B3FA5 Q30537307-950E725D-6DF1-473D-893E-EB96BB040EC8 Q30689252-042619AE-BC4E-4325-B33D-BD1A9973F2E1 Q30854772-7E158CEB-D895-4C06-90C9-2453708E91FF Q31161741-07F27B1F-66F7-48DB-87B9-4F3BE540FE0E Q33306793-FD0CDA6D-CF71-4DFF-8F16-7E2668B26D1E Q33320817-D18A210A-691D-4B89-90EA-0A9ED098C128 Q33435199-81CC60B2-CE51-400A-99C1-5A4559C59855 Q33554381-5492C4BD-793B-438A-BC83-7FB47C23C6F4 Q33580620-92F4E1B8-0206-4178-8B5D-E9528352FB1D Q33646447-8A75C97C-653B-415F-8879-A740FC7B2543 Q33792729-739843C0-46B9-48AA-8A9F-28283AC05C05 Q33808198-24908BE5-9ADA-43F4-B340-C14C6285D75F Q33948737-71E1C41B-2EAE-443E-958E-E84FA5731992 Q34019069-C6ED4205-24CC-45A4-9CC7-48CCEFE16D2B Q34170399-767739B7-82BE-44E0-BCE5-E7183E7F03AB Q34209358-67853CFD-9332-405F-A57A-810CF7A9BD95 Q34245348-3625574C-5E1D-49E7-8AC4-44F52BA98A10 Q35153219-84488A53-99D4-40E2-810B-64CA8711881D Q35153224-15A73C73-AECD-4B9F-B952-2130D181AA74 Q35536278-6277EF19-AB04-4BE3-8E6E-5EF692D0F9E6 Q35784515-E217F952-FA2D-47DB-98AA-C73B5477946A Q35797491-70E230AC-C229-42DD-8F55-F12DEF33A506 Q36110533-6AA4E4CB-1258-4962-B8EA-BDD8E9362A68 Q36121203-E262542E-84C3-4ACF-9CCF-2C86BD5B9F69 Q36176326-B81046F6-7B7E-4A65-8636-AC9B988B071B Q36407002-98015B6D-C6FC-461A-A78F-2BCD9B7206F9 Q36537025-A7912F3A-5AB5-499D-8C08-80FBF38519E4 Q37019579-93EEC4FA-2448-456A-A818-F55761F0FF59 Q37032687-144120E4-22E2-4486-898E-FDD279267925 Q37059195-ED2DE0BC-155B-4335-BB9B-09A0FA11A160 Q37175605-48F42F61-E328-4AD1-B3F6-A1265DC6A327

P2860

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.

http://www.wikidata.org/entity/Q33267693

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Par4 is required for platelet ...... n a mouse model of thrombosis.

@ast

Par4 is required for platelet ...... n a mouse model of thrombosis.

@en

Par4 is required for platelet ...... n a mouse model of thrombosis.

@nl

type

label

Par4 is required for platelet ...... n a mouse model of thrombosis.

@ast

Par4 is required for platelet ...... n a mouse model of thrombosis.

@en

Par4 is required for platelet ...... n a mouse model of thrombosis.

@nl

prefLabel

Par4 is required for platelet ...... n a mouse model of thrombosis.

@ast

Par4 is required for platelet ...... n a mouse model of thrombosis.

@en

Par4 is required for platelet ...... n a mouse model of thrombosis.

@nl

P1433

Q33267693-771CCE34-07B7-4DCE-AF1D-F7636224E59E

P1476

Q33267693-55EAC008-A7B9-4B54-80C4-168766830AE1

P2093

Q33267693-3E54A23F-1D08-4EAF-9CB2-10CC44F272A8

Q33267693-6A0F1A05-D46E-4095-9282-90C652A865E4

Q33267693-A19967A0-A5FE-4ECB-A60E-AD4C14FCB677

Q33267693-A2463D8C-1902-4C80-810D-4454EE9414FE

Q33267693-E47F4E54-799E-48E6-876B-9D77234EE09D

P2860

Q33267693-1C0935AF-C314-4D98-982B-8D22BE5DE9E8

Q33267693-1F3468D6-3501-4F05-AC31-AD4D46A67720

Q33267693-438E4951-3E26-4DBE-8E23-154A163EDF4D

Q33267693-4D47AE90-40B3-4096-AF5E-48F13D7F5CD2

Q33267693-5DED788E-50F8-4DFF-848B-59DADF4D7121

Q33267693-6B263596-FCA6-48F4-BF3D-A8B21857F54B

Q33267693-8B105B99-9362-441E-B368-F653DAE74030

Q33267693-A78804C1-5EA4-4635-90B5-E2A901AB951A

Q33267693-C9E7DBDB-DC50-4E70-B507-B8CF387E70CC

Q33267693-CB7FFC85-8552-436E-9ED5-EAF4743B33A4

P304

Q33267693-66182587-E52B-402A-B120-07F172FD4CA3

P31

Q33267693-893EAEBA-89EB-4D72-A5A3-82FDC834F6A3

P356

Q33267693-FFBC9C95-C2EE-4DCC-8950-5DF699EE5605

P407

Q33267693-CE8D7106-2632-4B69-B3C2-B567533B8640

P433

Q33267693-49431B4E-7808-4680-91FA-03BF8C9D9A87

P478

Q33267693-1A89BADB-49BE-48B3-AC3F-61232564D24D

P577

Q33267693-0D7EDDC4-5027-47CC-A9B2-3DC0997D344E

P5875

Q33267693-8F330F00-C82A-4225-8864-FDE864E3BB36

P698

Q33267693-24335312-27D0-424C-8C62-A67681387FAE

P921

Q33267693-4D90B45D-BFC9-4A7C-A4AC-71E5C059D5BE

P932

Q33267693-2C1F91C1-2A1D-4374-8CFE-98D2E6469B86

P356

PNAS.0610188104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Par4 is required for platelet ...... n a mouse model of thrombosis.

@en

P2093

Barbara C Furie

http://www.w3.org/2001/XMLSchema#string

Bruce Furie

http://www.w3.org/2001/XMLSchema#string

Erik R Vandendries

http://www.w3.org/2001/XMLSchema#string

Justin R Hamilton

http://www.w3.org/2001/XMLSchema#string

Shaun R Coughlin

http://www.w3.org/2001/XMLSchema#string

P2860

Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo

Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi

Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen

Thrombin signalling and protease-activated receptors

Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.

Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity.

MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice

Role of thrombin signalling in platelets in haemostasis and thrombosis.

Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.

Protection against thrombosis in mice lacking PAR3.

P304

288-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0610188104

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6609410

http://www.w3.org/2001/XMLSchema#string

P698

17190826

http://www.w3.org/2001/XMLSchema#string

P921

P932

1765451

http://www.w3.org/2001/XMLSchema#string